Newsletter summary
[Sainuo Medical's first intracranial stent has a remarkable curative effect, the second may be approved within this year] Securities Times, the affiliated Hospital of Tongji University announced todayStriopokerAccording to the research report, the restudy data of Saino Medical's first intracranial special stent for cerebral infarction (drug-eluting stent) is that the rate of restenosis in one year is 6.Striopoker.66%Striopoker...
Text of news flash
According to a research report released today by the affiliated Hospital of Tongji University, according to a research report released today by the affiliated Hospital of Tongji University, the re-study data of Sainuo Medical's first intracranial special stent for cerebral infarction (drug-eluting stent) is 6.66% in one year, which is 73.4% lower than that of bare stent, thus reducing recurrent stroke by 88.4%. Cerebral infarction is called ischemic stroke in medicine and stroke in folk. Studies conducted before the introduction of Saino Medical Intracranial Drug-Eluting Stents showed that in 2018, the restenosis rate of patients with cerebral infarction was 27.6% within one year after other stents were implanted, and in 2020, the restenosis rate was 17.6%. Compared with these two sets of data, the clinical data of Xeno medical drug-eluting stents are excellent. The study conducted by Fang Chun, director of the intervention Department of Tongji Hospital affiliated to Tongji University, was published in Neurointervention online today. Saino Medical Intracranial Drug-Eluting Stent was approved to be put on the market in July 2021. It is not only the first stent for intracranial artery stenosis in the world, but also the first intracranial drug stent without neurotoxicity and safety. Professor Fang Chun's team's research can be regarded as a post-market re-study. Cerebral infarction caused by intracranial artery stenosis accounts for 46.6% of the Asian population. Although drug therapy is still the first choice, there is still a certain risk of stroke recurrence even after intensive drug therapy. Especially in patients with severe arterial stenosis, the 1-year recurrence rate is as high as 20% and 30%. Professor Fang Chun's team said in the research report that there are few reports about the use of intracranial stents in the treatment of intracranial arterial stenosis, and this study was carried out in order to obtain more experience and evidence.StriopokerFrom December 2021 to May 2022, they received 24 patients with symptomatic severe intracranial artery stenosis treated with Cenotherapy intracranial drug-eluting stents. All of these patients were successfully implanted with Xeno medical drug-eluting stents, the residual stenosis was less than 30% (mild stenosis, generally asymptomatic), there were no bleeding complications or death, and the degree of stenosis decreased from 85.9% to 8.6% on average. One-year follow-up data showed that the 1-year restenosis rate was 6.66%, which was 73.4% lower than that of bare stents, thus reducing recurrent stroke by 88.4%. Vascular endothelial healing was guided, the drug reached its peak in 28 days and was absorbed in 60 days. At present, 13 nerve intervention products have been approved by Saino Medical, and the second cerebral infarction stent, self-expanding drug stent, has also passed the examination of innovative medical devices, with smaller delivery diameter, better vascular compliance in conical and curved vessels, and can be sent to more distant and circuitous blood vessels, which solves the problem of high requirements for vascular conditions in the area where drug ball dilatation stents are placed, and can be used more widely. It also improves the passability of the stent and the safety of perioperative period. It is better than intracranial drug-eluting stent in reducing the rate of restenosis. Pharmaceutical analysts generally expect it to be approved by the end of the year. (Yanyun) proofreading: Gao Yuan